Answers are grounded in this paper and cite their sources.
This study aimed to compare serum intercellular adhesion molecule-1 (ICAM-1) levels following human dental follicle-derived mesenchymal stem cell and microfracture treatments in a rabbit model of osteochondral cartilage damage. Female New Zealand rabbits aged 2–3 months and weighing approximately 2.5 kg were used in the study. The animals were divided into three groups: an untreated defect control group, a group treated with 5 × 10⁶ lyophilized human dental follicle-derived mesenchymal stem cells applied to the defect area (xenogeneic application), and a group in which five microfracture holes were created at the base of the defect. At 16 weeks postoperatively, serum ICAM-1 levels were measured in a total of 16 serum samples, including four animals in the defect control group, six animals in the mesenchymal stem cell group, and six animals in the microfracture group, using a sandwich ELISA assay. A significant difference was found among groups in serum ICAM-1 levels (P < 0.001). The highest serum ICAM-1 level was detected in the defect control group (262.28 ± 20.59 ng/L), while the lowest level was found in the mesenchymal stem cell group (142.29 ± 3.91 ng/L). In the microfracture group, the value was 210.15 ± 24.19 ng/L. These findings suggest that dental follicle-derived mesenchymal stem cell treatment was associated with lower terminal serum ICAM-1 levels than microfracture treatment or untreated defects. However, serum ICAM-1 is not cartilage-specific, and further studies are needed to clarify the biological significance of these findings.
No takes yet. Share an insight, caveat, or question.
YAĞCI et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: